HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ross, L. J. N. Articles by Scott, S. Search for Related Content PubMed PubMed Citation Articles by Ross, L. J. N. Articles by Scott, S. Agricola Articles by Ross, L. J. N. Articles by Scott, S.

Construction and properties of a turkey herpesvirus recombinant expressing the Marek's disease virus homologue of glycoprotein B of herpes simplex virus

L. J. N. Ross

M. M. Binns^>

J. Pastorek

S. Scott^>

AFRC Institute for Animal Health, Houghton Laboratory, Houghton, Huntingdon PE17 2DA, U.K.

A herpesvirus of turkeys (HVT) recombinant containing a 3.9 kbp fragment of Marek's disease virus (MDV) DNA encoding MDV glycoprotein B (gB), stably integrated into the thymidine kinase (TK) gene of HVT, has been constructed. The replication of the recombinant in chick embryo fibroblasts (CEF) was comparable to that of wild-type HVT. The recombinant expressed authentic MDV gB and its processed forms (110K, 65K and 48K) in CEF as shown by immunoblotting using an MDV-specific anti-peptide serum. Northern blot analysis showed that MDV gB mRNA was transcribed from MDV promoter sequences flanking the MDV gB open reading frame and also from the HVT TK promoter. However, the level of replication of the recombinant in vivo appeared to be lower than wild-type HVT as shown by the titres of HVT antibodies, determined by ELISA. Pathogenicity tests showed that the recombinant was safe and did not cause microscopic or gross Marek's disease lesions or other abnormalities. The results suggest that HVT has potential as a vector for recombinant vaccines.

Present address: AFRC Institute for Animal Health, Compton Laboratory, Newbury, Berks RG16 0NN, U.K.

^> Present address: Animal Health Trust, Newmarket, Suffolk, U.K.

Present address: Institute of Virology, Bratislava, Czechoslovakia.

Received 28 May 1992; accepted 19 October 1992.

This article has been cited by other articles:

				E Le Rouzic, P Thoraval, M Afanassieff, Y Cherel, G Dambrine, and B Perbal Alterations of the MDV oncogenic regions in an MDV transformed lymphoblastoid cell line Mol. Pathol., August 1, 2002; 55(4): 262 - 272. [Abstract] [Full Text] [PDF]

				K. Tsukamoto, S. Saito, S. Saeki, T. Sato, N. Tanimura, T. Isobe, M. Mase, T. Imada, N. Yuasa, and S. Yamaguchi Complete, Long-Lasting Protection against Lethal Infectious Bursal Disease Virus Challenge by a Single Vaccination with an Avian Herpesvirus Vector Expressing VP2 Antigens J. Virol., May 3, 2002; 76(11): 5637 - 5645. [Abstract] [Full Text] [PDF]

				K. Sonoda, M. Sakaguchi, H. Okamura, K. Yokogawa, E. Tokunaga, S. Tokiyoshi, Y. Kawaguchi, and K. Hirai Development of an Effective Polyvalent Vaccine against both Marek's and Newcastle Diseases Based on Recombinant Marek's Disease Virus Type 1 in Commercial Chickens with Maternal Antibodies J. Virol., April 1, 2000; 74(7): 3217 - 3226. [Abstract] [Full Text]